KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals provided an operational update and released financial results for the first fiscal quarter ended July 31, 2024. Highlights include the FDA's acceptance of the NDA for sebetralstat, an oral plasma kallikrein inhibitor for HAE, and the EMA's validation of the MAA. KalVista anticipates filing for approval in the UK, Japan, and other countries later in 2024, aiming for a June 2025 commercial launch. Financial results showed a net loss of $40.4 million, with R&D and G&A expenses increasing to $26.6 million and $17.6 million, respectively.
Reference News
KalVista Pharmaceuticals provided an operational update and released financial results for the first fiscal quarter ended July 31, 2024. Highlights include the FDA's acceptance of the NDA for sebetralstat, an oral plasma kallikrein inhibitor for HAE, and the EMA's validation of the MAA. KalVista anticipates filing for approval in the UK, Japan, and other countries later in 2024, aiming for a June 2025 commercial launch. Financial results showed a net loss of $40.4 million, with R&D and G&A expenses increasing to $26.6 million and $17.6 million, respectively.